Justia Products Liability Opinion Summaries

Three plaintiffs alleged they suffered injuries after receiving the Gardasil vaccine, which is designed to prevent certain strains of human papillomavirus. Each plaintiff experienced adverse symptoms following their Gardasil injections, but the onset of these symptoms occurred more than three years before they filed petitions for compensation under the National Vaccine Injury Compensation Program. The plaintiffs acknowledged to the special master that their petitions were untimely and sought equitable tolling of the Vaccine Act’s limitations period.The special master in the United States Court of Federal Claims found the petitions untimely and denied equitable tolling, resulting in dismissal of the claims. The plaintiffs then filed suit against Merck & Co. and Merck Sharp & Dohme LLC in the United States District Court for the Western District of North Carolina, which was handling multi-district litigation related to Gardasil. Merck moved to dismiss, arguing that the plaintiffs had failed to timely pursue their remedies under the Vaccine Act. The district court dismissed the complaints, holding that the proper forum for challenging the special master’s timeliness rulings was the Court of Federal Claims and the Federal Circuit, not the district court. The court also rejected a constitutional challenge to the process by which Gardasil was added to the Vaccine Injury Table.On appeal, the United States Court of Appeals for the Fourth Circuit affirmed the district court’s rulings. The Fourth Circuit held that the addition of Gardasil to the Vaccine Injury Table did not violate the Constitution. It further held that timely participation in the Vaccine Act compensation program is a prerequisite to bringing a tort suit, and that courts hearing vaccine-related tort suits may not reconsider the timeliness of a Vaccine Act petition once the special master has made a finding. The court affirmed the dismissal of the plaintiffs’ complaints. View "Needham v. Merck & Company Inc." on Justia Law

KeraLink International, Inc. operates a network of eyebanks and purchased surgical packs containing eyewash from Stradis Healthcare, LLC. The eyewash, supplied by Geri-Care Pharmaceuticals Corporation, was contaminated, rendering corneal tissue unusable. KeraLink sued Stradis and Geri-Care for strict products liability, and both were held jointly and severally liable for $606,415.49 plus prejudgment interest. Stradis sought indemnification from Geri-Care, claiming Geri-Care's primary culpability as the apparent manufacturer of the eyewash.The United States District Court for the District of Maryland awarded summary judgment to KeraLink on its strict products liability claim against both Stradis and Geri-Care. The court rejected the sealed container defense asserted by both defendants. Stradis then sought implied indemnification from Geri-Care, arguing that its liability was secondary. The district court agreed, granting Stradis summary judgment for indemnification but denied Stradis' request for attorneys' fees incurred in defending against KeraLink's suit.The United States Court of Appeals for the Fourth Circuit reviewed the case. The court held that the district court did not err in awarding Stradis implied indemnification against Geri-Care. The court found that Geri-Care's conduct as the apparent manufacturer of the contaminated eyewash was primarily culpable, while Stradis' conduct was secondary. The court also upheld the district court's denial of Stradis' request for attorneys' fees, citing the American Rule, which generally precludes the recovery of attorneys' fees as compensatory damages unless authorized by statute, rule, or contract. The Fourth Circuit affirmed the district court's judgment in all respects. View "Geri-Care Pharmaceuticals Corp. v. Stradis Healthcare, LLC" on Justia Law

In June 2015, Dylann Roof shot and killed nine people at Mother Emanuel AME Church in Charleston, South Carolina, including M.P.'s father, Reverend Clementa Pinckney. M.P., a minor, filed a lawsuit against Meta Platforms, Inc. (formerly Facebook, Inc.) and its subsidiaries, alleging that Facebook's algorithm recommended harmful content that radicalized Roof, leading to the murders. M.P. asserted claims of strict products liability, negligence, and negligent infliction of emotional distress under South Carolina law, as well as a federal claim under 42 U.S.C. § 1985(3) for conspiracy to deprive her of her civil rights.The United States District Court for the District of South Carolina dismissed M.P.'s complaint under Federal Rule of Civil Procedure 12(b)(6), concluding that Section 230 of the Communications Decency Act barred her state law tort claims. The court also found that M.P. failed to plausibly allege a claim under 42 U.S.C. § 1985(3).The United States Court of Appeals for the Fourth Circuit reviewed the case and affirmed the district court's decision. The appellate court held that M.P.'s state law tort claims were barred by Section 230 because they sought to hold Facebook liable as a publisher of third-party content. The court also determined that M.P. failed to plausibly allege proximate causation under South Carolina law, as her complaint did not provide sufficient factual foundation linking Roof's Facebook use to his crimes. Additionally, the court found that M.P. forfeited her challenge to the dismissal of her Section 1985 claim by not adequately addressing it in her appellate brief. The court also concluded that any potential claim under 42 U.S.C. § 1986 was barred by the one-year statute of limitations. Thus, the Fourth Circuit affirmed the district court's judgment granting Facebook's motion to dismiss. View "M.P. v. Meta Platforms Inc." on Justia Law

The Fourth Circuit affirmed the MDL court's partial summary judgment award and denial of plaintiff's motion to reconsider. Plaintiff filed suit against Boston Scientific, alleging that the transvaginal mesh product that the company manufactured injured her and that Boston Scientific failed to warn of risks associated with the mesh. Plaintiff joined an MDL and then lost her failure to warn claim at summary judgment. After the case was transferred to a district court for trial on the remaining claims, plaintiff moved to reconsider the summary judgment award based on evidence that she failed to cite during summary judgment briefing in the MDL court. The district court denied the motion and plaintiff subsequently lost at trial. The Fourth Circuit could not say that the MDL court erred in its summary judgment ruling based on the evidence plaintiff cited in opposition to summary judgment. The Fourth Circuit explained that the Federal Rules of Civil Procedure require parties to cite all evidence in support of their positions at summary judgment. Finally, the district court did not abuse its discretion by denying the motion to reconsider despite plaintiff’s citation to additional excerpts of plaintiff's treating phsysician's deposition establishing that he reviewed and was familiar with the Directions for Use (DFU). View "Carlson v. Boston Scientific" on Justia Law

Howard and Nancy Nease filed a products liability suit against Ford, alleging that Howard sustained serious injuries in an accident caused by a design defect in the speed control system of his 2001 Ford Ranger pickup truck. The jury awarded plaintiffs over $3 million in damages. The district court denied Ford's post-trial motions. The court concluded that the expert testimony of Samuel Sero regarding the speed control cable should not have been admitted. The court explained that Daubert v. Merrell Dow Pharmaceuticals, Inc. applies to Sero's testimony and the district court did not perform its gatekeeping duties with respect to Sero’s testimony. In this case, Sero’s testimony should have been excluded under Daubert because it was unsupported. Without any other expert testimony to establish that the 2001 Ford Ranger was defectively designed and that there were safer alternative designs available that a reasonably prudent manufacturer would have adopted, the court concluded that the Neases cannot prove their case under West Virginia law. Accordingly, the court reversed and remanded for entry of judgment in Ford's favor. View "Nease v. Ford Motor Co." on Justia Law

Plaintiff and her husband filed a products liability suit against Ethicon after she experienced complications from the implantation of a transvaginal mesh medical device. On appeal, Ethicon challenges the denial of its post-trial renewed motion for judgment as a matter of law or, in the alternative, for a new trial. The court affirmed the judgment, concluding that the district court did not commit reversible error where plaintiffs offered sufficient evidence to sustain the jury's general verdict for plaintiffs on their design defect, failure to warn, and loss of consortium claims. In this case, the district court did not err by excluding evidence of the FDA's section 510(k) evaluation process; excluding the FDA Advisory Committee evidence; and excluding evidence of the Prolene suture's regulatory history. View "Huskey v. Ethicon, Inc." on Justia Law

Plaintiff filed suit in Virginia state court against Appellants and others, alleging that plaintiff's husband, Bernard W. Ripley, was exposed to asbestos contained in products Appellants manufactured for the Navy, and that Appellants are liable for failure to warn of asbestos hazards. Appellants removed the case pursuant to the federal officer removal statute to the United States District Court for the Eastern District of Virginia. The district court remanded to state court, citing longstanding precedent in the district that denies the government contractor defense in failure to warn cases. However, given the weight of opposing precedent and the rationales supporting the defense, the court held that the government contractor defense is available in failure to warn cases. Accordingly, the court reversed and remanded for the district court to consider whether Appellants have presented sufficient proof to warrant removal pursuant to 28 U.S.C. 1442. View "Ripley v. Foster Wheeler LLC" on Justia Law

This appeal stems from multi-district litigation involving transvaginal mesh medical devices used to treat pelvic organ prolapse and other pelvic issues. The jury awarded plaintiff $250,000 in compensatory damages, and the punitive damages award was split pursuant to a Georgia statute, with seventy-five percent going to the State of Georgia and twenty-five percent going to plaintiff. Both parties appealed. The court affirmed the district court's exclusion of evidence that Bard had complied with the FDA's 510(k) product safety process under F.R.E. 402 for lack of relevance; affirmed the district court's decision to admit evidence of a material data safety sheet pertaining to polypropylene, a material used in the construction of the Avaulta Plus implanted in plaintiff's body, as non-hearsay, finding that any use of the evidence by plaintiff that went beyond the limited purpose for which it was admitted as non-hearsay resulted in harmless error and was not prejudicial to Bard’s defense; and concluded that the district court did not err in giving the Georgia pattern jury instruction, in denying Bard’s request for a modified instruction, or in upholding the jury’s causation finding. The court also concluded that the punitive award was not constitutionally excessive. In regard to plaintiff's challenges, the court affirmed the district court's conclusion that Georgia's split-recovery statute garnishing seventy-five percent of any punitive damages award arising from a product liability judgment does not violate the Takings Clause of the Fifth Amendment. Accordingly, the court affirmed the judgment. View "Cisson v. C. R. Bard, Inc." on Justia Law